Company / R&D Expense
Lexaria Bioscience Corp. R&D Expense History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.4M
FY2025
5-year range
$387.1K / $3.7M
FY2021-FY2025
Trend
-35.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 10 years, ranging from $0 in FY2015 to $4M in FY2024.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +33.5%.
Improved from $2M to $2M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +23.2%
- 5-Year CAGR
- +33.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +33.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 35.6% year-over-year.
- Peak r&d expense was recorded in FY2024.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -35.6% |
| FY2024 | $3.7M | +99.0% |
| FY2023 | $1.8M | +45.9% |
| FY2022 | $1.3M | +226.3% |
| FY2021 | $387.1K | -30.3% |
| FY2020 | $555.7K | +12.8% |
| FY2019 | $492.9K | +5361.7% |
| FY2017 | $9.0K | -93.8% |
| FY2016 | $146.5K | - |
| FY2015 | $0 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026